J Cancer 2019; 10(7):1663-1674. doi:10.7150/jca.28231 This issue
1. Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, China;
2. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China;
3. Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
# Both authors contributed equally.
* Both authors contributed equally.
Available studies demonstrate that receptor-type tyrosine-protein phosphatase zeta (PTPRZ1) is expressed in different tumor tissues, and functions in cell proliferation, cell adhesion and migration, epithelial-to-mesenchymal transition, cancer stem cells and treatment resistance by interacting with or binding to several molecules. These included pleiotrophin (PTN), midkine, interleukin-34, β-catenin, VEGF, NF-κB, HIF-2, PSD-95, MAGI-3, contactin and ErbB4. PTPRZ1 was involved in survival signaling and could predict the prognosis of several tumors. This review discusses: the current knowledge about PTPRZ1, its expression, co-receptors, ligands, functions, signaling pathway, prognostic values and therapeutic agents that target PTPRZ1.
Keywords: PTPRZ1, pleiotrophin, midkine, review